K. Khunti

First name
K.
Last name
Khunti
Paul, S. K., Klein, K., Thorsted, B. L., Wolden, M. L., & Khunti, K. (2015). Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. http://doi.org/10.1186/s12933-015-0260-x
de Lusignan, S., Liaw, S. T., Dedman, D., Khunti, K., Sadek, K., & Jones, S. (2015). An algorithm to improve diagnostic accuracy in diabetes in computerised problem orientated medical records (POMR) compared with an established algorithm developed in episode orientated records (EOMR). J Innov Health Inform. http://doi.org/10.14236/jhi.v22i2.79
Chang, K. C., Lee, J. T., Vamos, E. P., Soljak, M., Johnston, D., Khunti, K., et al. (2016). Impact of the National Health Service Health Check on cardiovascular disease risk: a difference-in-differences matching analysis. Cmaj. http://doi.org/10.1503/cmaj.151201
Danese, M. D., Gleeson, M., Kutikova, L., Griffiths, R. I., Azough, A., Khunti, K., et al. (2016). Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open. http://doi.org/10.1136/bmjopen-2016-011805
Paul, S. K., Klein, K., Majeed, A., & Khunti, K. (2016). Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes. J Diabetes. http://doi.org/10.1111/1753-0407.12302
Khunti, K., Nikolajsen, A., Thorsted, B. L., Andersen, M., Davies, M. J., & Paul, S. K. (2016). Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. http://doi.org/10.1111/dom.12626
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., et al. (2017). Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo. Circulation. http://doi.org/10.1161/circulationaha.117.029190
Danese, M. D., Gleeson, M., Kutikova, L., Griffiths, R. I., Khunti, K., Seshasai, S. R. K., & Ray, K. K. (2017). Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open. http://doi.org/10.1136/bmjopen-2016-013851
Wilding, J. P. H., Godec, T., Khunti, K., Pocock, S., Fox, R., Smeeth, L., et al. (2017). Changes in HbA1c and weight after initiation of second-line therapy in patients with type 2 diabetes in clinical practice. Diabetologia.
Cavender, M. A., Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Wilding, J. P., Khunti, K., et al. (2018). SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol. http://doi.org/10.1016/j.jacc.2018.01.085